[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467294":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":34,"locations":41,"responsibleParty":58,"collaborators":21,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":21,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":21,"overallStatus":44,"whyStopped":21,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"ANCA-associated vasculitis - patient library","It is a description of ANCA-associated vasculitis patients cohort. All the patients are included in one arm. They will undergo various type of samples.",[12,13,14,15],"Other: Blood samples (80 mL)","Other: Fecal samples","Other: Urinary sample (20-40 mL)","Other: Questionnaires",[17,22,26,30],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"Blood samples (80 mL)","Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Fecal samples","Fecal samples at inclusion",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":21},"Urinary sample (20-40 mL)","Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment",[9],{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":21},"Questionnaires","Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment",[9],[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Divi CORNEC","CONTACT","(0)2 98 34 72 64","+33","divi.cornec@chu-brest.fr",[42],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"CHRU de Brest - Service de rhumatologie","RECRUITING","Brest","29200","France","FR",{"type":50,"coordinates":51},"Point",[52,53],-4.48628,48.39029,{"lat":53,"lon":52},[56],{"name":36,"role":37,"phone":57,"phoneExt":21,"email":40},"02 98 34 72 64",{"type":59,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100467294","biocollection-of-patients-with-anca-associated-vasculitis-100467294",false,"NCT05364892","Biocollection of Patients With ANCA Associated Vasculitis","Biocollection of Patients With ANCA Associated Vasculitis Diagnosed Within the CERAINO Autoimmune Disease Reference Center, Part of the Global BRAISE Project (B-dependent Rare AutoImmune DiseaSES","ANCA","Inclusion Criteria:\n\n* Major patients with no upper age limit.\n* Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest.\n* Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference.\n* Patient affiliated with Social Security\n* Patient who has signed written informed consent\n\nExclusion Criteria:\n\n* Minor\n* Patients unable to consent.\n* Patients refusing to participate in research\n* Patient under legal protection (tutelage, curatorship)\n* Pregnant or lactating women\n* Hemoglobin (Hb) \\\u003C 7g\u002FdL",true,"ALL","18 Years","99 Years",{"count":73,"type":74},100,"ESTIMATED","INTERVENTIONAL",[77],"NA","As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to be elucidated. The collection of standardized data within a patientheque as part of a multi-year follow-up will facilitate the study of the characteristics of these diseases. This may, in particular, address the main objective of identifying predictors of relapse, as well as secondary objectives for predictive factors of mortality, infectious, cardiovascular or neoplastic complications that affect the prognosis of vasculitis in order to establish a more appropriate management of the patients concerned.",[80],"ANCA-associated Vasculitis","2026-06-24",{"date":83,"type":84},"2026-06-25","ACTUAL",{"date":86,"type":84},"2022-10-27",{"date":88,"type":74},"2032-10-27",{"name":5,"class":6},1]